Bristol-Myers Squibb Co
BMY:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 41.61 | -0.69 -1.63% | 3.31% | 3,189,593 | 8.7M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Bristol-Myers Squibb Co
Santaris forms alliance with Bristol-Myers to develop RNA-targeted medicines
Santaris Pharma A/S, a biopharmaceutical company, has announced a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid, or LNA, Drug Platform.
Bristol-Myers Squibb: The Winning Streak Continues (BMY)
Bristol-Myers Squibb (NYSE:BMY) traded today at a new 52-week high of $42.87. So far today approximately 7.2 million shares have been exchanged, as compared to an average 30-day volume of 10.1 million shares.
For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
View more recent headlinesDecision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the numerous therapies in clinical development for extensive-disease small-cell lung cancer (ED-SCLC), no emerging therapy is likely to replace etoposide (Bristol-Myers Squibb's Etopophos/VePesid, generics)/carboplatin (generics) as the standard of care before 2022. Interviewed experts complain that treatment for SCLC has changed very little in decades, and--given the challenges of treating this aggressive disease and the current clinical pipeline--experts are pessimistic that the treatment landscape will improve in the near future.
Company Background
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 42.26 | Previous Close 42.30 |
Day High 42.28 | Day Low 41.56 |
52wk High/Date 42.87 / 4/23/2013 | 52wk Low/Date 30.64 / 11/15/2012 |
% off 52wk High -2.94% | % off 52wk Low 35.80% |
Beta (5 Yr) 0.4 | Market Capitalization 68.4B |
Shares Outstanding 1.6B | Volatility Avg 17.45 |
EPS(TTM) 1.15 | P/E Ratio 36.1x |
Dividend Announcement 3/7/2013 | Dividend Yield 3.31% |
Ex-Date 4/3/2013 | Date of Record 4/5/2013 |
Payable 0.35 - QRTR | Payable Date 5/1/2013 |
Last Trade as of 4/24/2013 12:02 PM ET | |
BMY Bristol-Myers Squibb Co vs. Peers
| Peers | |
|---|---|
BMY Bristol-Myers Squibb Co | 29.79% |
Johnson & Johnson | 21.90% |
Pfizer Inc. | 23.93% |
Merck & Co., Inc. | 18.78% |
BMY Bristol-Myers Squibb Co | 3.36% |
Johnson & Johnson | 2.86% |
Pfizer Inc. | 3.09% |
Merck & Co., Inc. | 3.54% |
BMY Bristol-Myers Squibb Co | -1.63% |
Johnson & Johnson | -0.66% |
Pfizer Inc. | -0.53% |
Merck & Co., Inc. | -0.95% |